Introduction
In vivo assays are a critical component of genotoxicity testing. Most often, a two-tiered integrated testing approach is used. Tier 1 includes in vitro assays. Tier 2 involves the use of shortterm in vivo studies [usually a bone marrow cytogenetics assay but also unscheduled DNA synthesis (UDS) or comet assay] to assess whether any potential for mutagenicity detected at the Tier 1 in vitro stage is actually expressed in the whole animal. Thus, negative results in vitro are usually considered sufficient to indicate lack of mutagenicity, whereas an in vitro positive result is not considered sufficient to indicate that the chemical represents a mutagenic hazard (i.e. it could be a false positive). The above concept applies to genotoxicity testing both when aimed at ascertaining the mutational potential of chemicals and when used to predict carcinogenicity. In special testing programs on chemicals with high impact on consumers (e.g. pharmaceutical drugs, agrochemicals), in vivo testing is required even when in vitro tests are negative. However, there is growing evidence that in vivo genotoxicity assays have a limited sensitivity. A recent analysis of a very large, commercial database of in vivo micronucleus results has shown that not only it is poorly correlated with rodent carcinogenicity but also responds negatively to many carcinogens that induce gene and chromosomal aberrations (1) . This lack of sensitivity is generally ascribed to restrictions in terms of tissues examined, as well as to absorption, distribution, metabolism and excretion (ADME) problems. The low sensitivity is likely to be a consequence of low exposure of target cells in vivo. Thus, it is necessary that evidence of target cell exposure is obtained in such studies in order to decide if a negative result is real or it is only inconclusive (2) .
Recently, a collaboration has been established between the Federal Office of Public Health of Switzerland and the Italian National Institute of Health (Istituto Superiore di Sanita') in order to build a high-quality database of in vivo micronucleus mutagenicity test results. The aim is to provide a basis for toxicological evaluations. This database, called ISSMIC, has been donated to the Organization for the Economic Cooperation and Development (OECD) to be incorporated into the OECD (Q)SAR Toolbox. The Toolbox is a freely available software containing an array of tools that permit the prediction of toxicological properties of chemicals by extrapolating from similar chemicals with measured properties (using, e.g. Readacross and Category formation procedures): http://www.oecd. org/document/54/0,3746,en_2649_34373_42923638_1_1_1_ 1,00.html.
At present, ISSMIC v4a contains 566 chemicals. Data were retrieved from different literature and databases sources and were critically reviewed. As evidence about the target cell exposure is critical to judge the results of this test, toxicity data were critically reviewed as well and included in the database. In this paper, ISSMIC is investigated in terms of relationships of the in vivo micronucleus with carcinogenicity and other genotoxicity events. Structural Alerts (SA) and chemical determinants are also considered. The role of the in vivo micronucleus test in genotoxicity testing is discussed.
Data and methods
The in vivo micronucleus data were retrieved from the ISSMIC v4a database. ISSMIC is part of the ISSTOX project of the Istituto Superiore di Sanita', aimed at building curated, high-quality databases on chemical toxicity. At present, ISSTOX consists of three databases: (i) ISSMIC, on in vivo micronucleus test results; (ii) ISSCAN, on chemical carcinogenicity experiments in rodents. When available, it also reports Ames test data for the chemicals bioassayed; and (iii) ISSSTY, on Salmonella typhimurium (Ames test) results. The databases are freely available from the website: http:// www.iss.it/ampp/dati/cont.php?id5233&lang51&tipo57.
The organization of the databases is inspired by that of the Distributed Structure-Searchable Toxicity (DSSTox) Network of the US Environmental Protection Agency (http://www.epa.gov/nheerl/dsstox/) and is described in Benigni et al. (3) . Similarly to the DSSTox spirit, this project wants to contribute to the free diffusion of scientific data in a standardized, easy to read format. Specific features of each database (e.g. experimental systems, references, etc.) are provided in the included documentation.
The carcinogenicity and Salmonella mutagenicity data used in this analysis were retrieved from the ISSCAN v3a database, whereas the data relative to the in vitro chromosomal aberrations assay were retrieved from the Kirkland-Lhasa compilation (4) . ISSCAN v3a is a curated database that collects results obtained with the classical rodent bioassay. The rodent bioassay is currently the main tool in the assessment of the carcinogenic risk to humans (5, 6) . ISSCAN v3a consists of results relative to 1153 chemicals. The carcinogens are 718. As judged from the presence of overtly DNA-reactive moieties, out of them 492 ($70%) have genotoxic mechanisms of action and may constitute a potential risk to humans.
Results and discussion
ISSMIC is a curated, high-quality database on in vivo micronucleus test data. The survey and critical review of the literature resulted in a database including 566 chemicals. Particular attention was given to the definition of negative results. Very often, especially in old literature, negative calls are reported without any evidence that the chemicals actually interacted with the target cells (e.g. bone marrow cells). In the preparation of ISSMIC, the target cells toxicity was given the highest priority as demonstration of interaction with target cells, and for each experiment, the available data were included in the database. In its present version (Table I) , ISSMIC results are stratified into the categories of: (i) positives (n 5 190); (ii) borderline results (n 5 48); (iii) negatives with clear evidence of cell exposure (n 5 97), and (iv) inconclusives (n 5 231). Inconclusive results include: (i) chemicals that neither induce micronuclei nor target cells toxicity and (ii) chemicals that do not induce micronuclei and for which target cell toxicity information is not available in the literature. Borderline results include chemicals that gave borderline results in at least one of the assay systems used. In this context, the operational category of 'inconclusives' deserves some additional comments. In the absence of clear toxicity at target cells, a widely used metric is toxicity to the whole animal, and in the absence of toxicity, many chemicals are tested up to the limit dose of 2000 mg/kg. Especially in some testing programs (e.g. pharmaceutical drugs), a chemical that does not induce micronuclei and has been tested up to the limit dose is considered to be a valid negative result. This position has both pros and cons. The pros are that there may be non-genotoxic chemicals which are non-toxic for bone marrow cells even at the maximum feasible dose. The cons are that general toxicity and genotoxicity are not overlapping phenomena and that the lack of toxicity at the bone marrow cells cannot exclude toxicity (and genotoxicity) at other cells. In any case, there is no doubt that toxicity at target cells is a much more cogent proof of interaction that the two surrogate criteria (toxicity to the whole animal and attainment of the limit dose). For the above reason, we decided to keep the following analyses of this work on a firm ground and used only the clear Positives and Negatives. It should be noticed that the total number of in vivo micronucleus results (almost 300 chemicals) in the above categories is considerably higher than in any previous analysis in the literature [e.g. Shelby et al. (7) and Kirkland and Speit (8)]. In addition, as demonstrated in the following analyses, the data used are quite well balanced in terms of mechanisms of action since they include carcinogens (both genotoxic and non-genotoxic) and non-carcinogens, and chemicals positive and negative in S. typhimurium and in the in vitro chromosomal aberrations test. Last but not least, the chemicals considered represent many different chemical classes (details are given below in the analysis on the SA).
Relationships with other end points
The analysis on the relationship between induction of micronuclei in vivo and induction of related end points (i.e. in vitro gene mutation and chromosomal damage, carcinogenicity) was performed by comparing the ISSMIC database with results from other databases (see Data and methods). Table II shows the relationship between in vivo micronucleus and a typical gene mutation-based system like the S. typhimurium test. The statistics of the table is: chi-square 5 5.3463, with P 5 0.0208. The statistically significant correlation points to a partial overlapping of mechanisms of action, probably related to the common sensitivity to DNA-reactive chemicals. Table III displays the relationship between in vivo micronucleus and in vitro chromosomal aberrations, with chi-square 5 0.4246 and P 5 0.5146. In spite of the common genetic end point, the two experimental systems are not correlated in a statistically significant way. The quite high number of in vivo positives that are negative in vitro may be due to aneugenic mechanisms of action that are not detected by the in vitro chromosomal aberrations test. Table IV reports the correlation between in vivo micronucleus and the rodent carcinogenicity results, with chi-square 1.0827 and P 5 0.2981. No statistically significant correlation is apparent as well. The mechanistic representativity of the data set in Table IV In vivo micronucleus in genotoxicity testing strategy In the common practice, an adequate evaluation of the genotoxic potential of a chemical substance involves the use of tests based on different genetic end points, i.e. induction of gene mutations, structural (clastogenic) and numerical (aneugenic) chromosomal alterations. Even though often overlooked, a distinction should be made between criteria to be used when genotoxicity testing is aimed at ascertaining mutational potential and when it is aimed at predicting carcinogenicity. In the former case, the panel of tests should cover the whole spectrum of genetic events. Here, there are no false positives or negatives, and the genetic end points have a value per se. On the other hand, the use of mutagenicity tests to predict carcinogenicity is subjected to operational constraints, and the selection of tests should be guided by the correct prediction of the golden standard represented by the carcinogenicity results. Since-because of the limitations of epidemiology-only a limited number of human carcinogens is known, the rodent bioassay results are used as golden standard in this type of analyses (5, 6) .
Regarding the prediction of carcinogenicity, all the evidence accumulated in decades converges towards the notion that only the Ames test is statistically correlated with carcinogenicity. It appears that the DNA-reactive chemicals tend to be positive in Salmonella as well as in the other genotoxicity tests and to be carcinogenic as well. A Salmonella positive has a high probability of being also a carcinogen. On the contrary, for genotoxic chemicals that are negative in Salmonella while being positive in other tests (as, e.g. chromosomal aberrations), there is no correlation with (and predictivity of) carcinogenicity. This explains why adding further tests to Salmonella in a battery does not improve carcinogenicity prediction (9,10). As a consequence, the types of tests required and-most importantly-the way of considering the test results should be different when genotoxicity testing is aimed at assessing mutational risk and when it is aimed at predicting carcinogenicity.
In this section, we use the ISSMIC results to test the role of the in vivo micronucleus assay within a strategy of prescreening of carcinogenicity.
The lack of overall correlation between the in vivo micronucleus assay and carcinogenicity shown in Table IV indicates that the assay-as standalone tool-is not a reliable predictor. Since in many testing programs in vivo testing is elicited by in vitro positive results, a first analysis considers how the in vivo micronucleus test helps in discriminating between carcinogens and non-carcinogens in the subset of chemicals positive in the Ames test. Table V displays the relationship between in vivo micronucleus and carcinogenicity in the above subset of mutagens. A first observation is that 50 out 54 Ames mutagens are also carcinogens: in other words, the Positive Predictivity of the Ames test is extremely high in this set of chemicals. The other observation regards the ability of in vivo micronucleus of discriminating between false (i.e. non-carcinogens) and true (i.e. carcinogens) Salmonella positives. It appears that the proportion of carcinogens is the same ($90%) both among in vivo micronucleus negatives and positives. This observation goes hand in hand with the other observation that, among the 54 Ames positives there are only 4 incorrect predictions (false positives). On the contrary, the in vivo micronucleus performed on the Ames positives leads to predict erroneously 13 chemicals (3 false positives plus 10 false negatives). Thus, performing an in vivo micronucleus test impairs the predictions based solely on the Ames test and has no added value.
A similar comparison of in vivo micronucleus and carcinogenicity is performed in the subset of chemicals that induce in vitro chromosomal aberrations (a situation that elicits in vivo testing). The results in Table VI are similar to those in Table V . There is a high proportion ($85%) of carcinogens both among in vivo micronucleus negatives and positives and the number of The table reports the distribution of results from the in vitro chromosomal aberrations test and the in vivo micronucleus in the databases used for this study. The table reports the distribution of results from the rodent bioassay and the in vivo micronucleus in the databases used for this study. The table reports the distribution of results from the rodent bioassay and the in vivo micronucleus among the chemicals positive in the Salmonella assay.
The new ISSMIC database on in vivo micronucleus incorrectly predicted chemicals (6 plus 15) resulting from performing an in vivo micronucleus on the in vitro clastogens is higher than those incorrectly predicted by the in vitro test alone (3 plus 6). The 70 chemicals in Table VI were further characterized in terms of mechanisms of action: 38 chemicals are positive in the Ames test and 29 are negative. Thus, the data set is representative of different mechanisms of action and includes both DNAreactive and non-DNA-reactive inducers of chromosomal damage. The analysis, when repeated separately on the two subsets of chemicals, confirmed the overall result of Table VI (results not shown).
Thus, Tables V and VI agree in pointing out that the in vivo micronucleus test is not a useful tool to assess the 'true' carcinogenic potential of in vitro genotoxic chemicals.
Mechanisms of action and SA in the updated in vivo micronucleus database The SAs are chemical reactive groups and structural motifs recognized as being linked with a given biological activity. A popular compilation of SAs is that curated by John Ashby based on the evidence on chemical carcinogenicity (11) . Since most of the carcinogens known at the time were DNA reactive (12, 13) , the Ashby's compilation of SAs applies to Salmonella mutagenicity as well (14) . An updated version of the carcinogenicity/mutagenicity SAs has been implemented as a module of the expert system Toxtree (15, 16) . Toxtree (http:// ecb.jrc.ec.europa.eu/qsar/qsar-tools/index.php?c5TOXTREE) is an open-source, freely available software application that places chemicals into categories and predicts various kinds of toxic effect by applying various decision tree approaches. Toxtree was developed by IdeaConsult Ltd (Sofia, Bulgaria) under the terms of an ex-European Chemicals Bureau contract (17) . Recently, the carcinogenicity/mutagenicity rule has been implemented into the OECD (Q)SAR Toolbox as well.
In our laboratory, we have previously defined a compilation of SAs for the in vivo micronucleus assay (18) . These SAs also have been implemented into Toxtree and the OECD (Q)SARToolbox. When the SAs were applied to the database used in our previous paper (1), a striking evidence was the low Positive Predictivity of the individual SAs. For a SA, Positive Predictivity is the percentage of toxic chemicals (here, micronuclei-inducing chemicals) out of the total number of chemicals containing the given SA. So, Positive Predictivity is an essential parameter to judge how likely a chemical with a given SA may be considered potentially toxic, and-at the same time-how reliable is an SA as predictive tool. For a comparison, the Positive Predictivity of the Toxtree carcinogenicity/mutagenicity rulebase is $80% for carcinogenicity and $70% for Ames mutagenicity, whereas the Positive Predictivity of the micronucleus SAs resulted to be only 33% (thus with a high proportion of false positives) (1) .
The critically revised in vivo micronucleus database presented in this paper gives the opportunity to assess the micronucleus SAs on a set of high-quality biological data. The inconclusive results were excluded from the analysis. Table VIIa displays the Positive Predictivity of the in vivo micronucleus SAs, based on the ISSMIC chemicals. Focusing on the SAs present in at least 10 chemicals, Positive Predictivity is now $80% or higher, with the notable exception of SA34 (63%) (definition below). Since many SAs are poorly represented in the database, we grouped together mechanistically related SAs (16), and we formed larger sets for: (i) direct alkylating, (ii) indirect alkylating, and (iii) arylamino/nitro chemicals (Table VIIb) . These larger categories are more representative from a statistical point of view. Overall, it appears that the Positive Predictivity is in the range 73-86%. Thus, when only reliable micronucleus results are used, the micronucleus SAs have a good Positive Predictivity and represent quite faithfully a number of the mechanisms of action underlying the induction of micronuclei.
Whereas Positive Predictivity is a measure of the reliability of the individual SAs, the overall adequacy of an SAs compilation is provided by global parameters such as Sensitivity, Specificity and Accuracy in respect to a toxicological end point (here, in vivo micronucleus). Figure 1 is a receiver operating characteristics graph that summarizes the above parameters. Figure 1 compares two applications of the SAs compilation: (i) with all SAs considered and (ii) excluding SA_34. SA_34 is an alert that encodes a complicated structural motif potentially able of noncovalent interactions with proteins or DNA (18) . Table VII shows that SA_34 is present in a large number of chemicals, with a low Positive Predictivity. Figure 1 shows that SA_34 contributes to increase remarkably Sensitivity (71%) at the cost of a poorer Specificity (32%). The latter is in agreement with the low Positive Predictivity of this Alert, which generates many false-positive results (Table VII) . On the other hand, removal of SA_34 increases Specificity (65%) but decreases Sensitivity (53%).
Taken together, the above results indicate that individually the SAs (except maybe SA_34) code for mechanisms of action that actually are important in the induction of micronuclei (high Positive Predictivity), but there are still mechanisms of action that are not covered by the presently available compilation of SAs.
Conclusions
The construction of a curated database on in vivo micronucleus mutagenicity results provides the basis for a refined analysis of several issues related to in vivo genotoxicity testing. The new database includes, together with evidence on the induction of micronuclei, also evidence on concomitant cell target toxicity. It is demonstrated that a large proportion of results (231 out 566 ISSMIC chemicals) should be operationally classified as 'inconclusive', since the lack of induction of micronuclei is not accompanied by clear-cut, direct demonstration of toxicity at the target cells.
Another interesting result provided by the analysis of ISSMIC is relative to the predictive ability of the SAs specific for in vivo micronucleus. In a previous paper, the SAs were applied to a database with a large proportion of negative results-based on the calls reported by the authors themselves. The SAs showed quite a low Positive Predictivity (an average 33%), i.e. many chemicals with SAs had negative calls (1) . In this paper, the SAs were applied to ISSMIC with the exclusion of the inconclusive results. The high Positive Predictivity with the ISSMIC chemicals ($80%) indicates that the SAs in the compilation are a reliable codification of mechanisms of micronuclei induction and can be used for predictive purposes. However, the Positive Predictivity varies between the different individual SAs. For example, SA_10 (coding for ab-unsaturated aldehydes) has a high Positive Predictivity (85%), whereas SA_34 has a much lower Positive Predictivity (63%). The availability of this information is important for the user, which in this way is provided with a measure of the reliability of the individual predictions and can decide the most adequate use according to different requirements and frameworks. Together with the reliability of the present SAs, the structural analysis of ISSMIC also points to the need of further expanding the list of mechanisms of action coded by SAs.
The ISSMIC database permits the re-evaluation of the role of in vivo micronucleus in strategies for genotoxicity testing as well. Given the cost in animal lives and the time required for the experimentation, in many testing programs, the in vivo mutagenicity tests are used only to assess in vitro positive results. Within such tiered schemes, the ability of in vivo micronucleus to identify real positives (i.e. carcinogens) among chemicals positive in Salmonella (Table V) or chemicals inducing in vitro chromosomal aberrations (Table VI) was studied. It appears that in the in vivo micronucleus test does not have added value and impairs the carcinogenicity prediction ability of the in vitro tests alone. This, together with evidence on a low overall correlation with carcinogenicity (Table IV) , indicates that in vivo micronucleus cannot be considered an useful tool in routine assessment of chemical carcinogenicity.
The present results, obtained on a larger database, confirm previous observations by other authors on more limited sets of chemicals. In a seminal work on 49 National Toxicology Program chemicals, the mouse bone marrow micronucleus protocol generated several false negative results, together with some false-positive results (7) . A project on screening human carcinogens classified by the International Agency for Research on Cancer (IARC) showed that the positive rates of micronucleus results for Groups 1, 2A, and 2B were 68.65, 54.5, and 45.6%, respectively. The micronucleus test was sensitive only to a number of chemical classes. No evaluation of specificity was possible because there are no recognized human non-carcinogens in the IARC classification (21) . A more recent analysis confirmed the low sensitivity of the micronucleus assay toward rodent carcinogens. The inspection of the subset of the micronucleus-negative carcinogens showed that 'many were multi-site, trans-species carcinogens, and therefore we might have expected the bone marrow to be a suitable target for genotoxicity in vivo' (8) . Thus, it appears that to predict carcinogenicity, other alleys should be explored.
In this regard, we recently showed that a two-tiered approach based on the Ames test and on the Syrian Hamster Embryo cells transformation assay is able to detect up to 90% of carcinogens (22) . Among the advantages of the above strategy, the fact that both tests are in vitro and that the Ames test can be efficiently The table reports the distribution of the SAs for micronucleus in the ISSMIC v4a database. The SAs are implemented in the expert system Toxtree (18) . For each alert, the table reports: (i) the number of substances with the alert, (ii) the number of chemicals positive in the micronucleus test (out of those with the SA), and (iii) the percentage of micronucleus-positives to the total number of chemicals with the alert [Positive Predictivity (%)]. In bold are the SAs present in at least 10 chemicals. Fig. 1 . The receiver operating characteristics graph in the figure displays the agreement between the in vivo micronucleus assay results and the SA for micronucleus implemented in Toxtree, with and without the SA_34 alert (see details in the text). The True positive rate corresponds to Sensitivity, and the False positive rate corresponds to 1-Specificity (19, 20) .
The new ISSMIC database on in vivo micronucleus replaced by SAs should be emphasized. The weak side of the above strategy is a relatively low specificity (even though considerably better than using traditional mammalian in vitro assays, such as Mouse Lymphoma mutations). The original idea of using in vivo mutagenicity tests is that they model more closely the ADME factors involved in the carcinogenicity process, and so should be able to filter positive results specific to in vitro systems. Unfortunately the in vivo micronucleus assay, which is the only in vivo genotoxicity test with ample applications, does not seem able to play efficiently this role in its present form, whereas other in vivo tests-after decades of research-are still under study and development. For example, among the complementary/alternative-to-micronucleus in vivo genotoxicity tests, there are UDS, transgenic mutations (TG) and comet assays. UDS is generally recognized to be quite disappointing (insensitive to carcinogens), whereas TG and Comet are still in the category of 'promising' assays (not enough data to be reliably assessed, especially with non-carcinogens) (8) . Comet has also reproducibility problems (23) . Thus, the entire issue still needs adequate solutions.
Regarding the use of genotoxicity testing for ascertaining the mutagenic potential of chemicals, recent studies have pointed to the possibility of using a combination of the Ames test and of in vitro micronucleus to cover the whole spectrum of genetic end points (24) . All the above evidence, together with its applicability limited to the cases where there is clear evidence of target cells toxicity, indicates that the role of in vivo micronucleus should not be in routine testing of chemicals, but in targeted mechanistic studies [see, e.g. Leopardi et al. 
